DE602004007225T2 - Methode zur behandlung von erkrankungen der unteren harnwege - Google Patents
Methode zur behandlung von erkrankungen der unteren harnwege Download PDFInfo
- Publication number
- DE602004007225T2 DE602004007225T2 DE602004007225T DE602004007225T DE602004007225T2 DE 602004007225 T2 DE602004007225 T2 DE 602004007225T2 DE 602004007225 T DE602004007225 T DE 602004007225T DE 602004007225 T DE602004007225 T DE 602004007225T DE 602004007225 T2 DE602004007225 T2 DE 602004007225T2
- Authority
- DE
- Germany
- Prior art keywords
- use according
- drug
- bladder
- esters
- amides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 118
- 150000001875 compounds Chemical class 0.000 claims abstract description 108
- 208000024891 symptom Diseases 0.000 claims abstract description 42
- 206010029446 nocturia Diseases 0.000 claims abstract description 17
- 208000026723 Urinary tract disease Diseases 0.000 claims abstract description 6
- 208000014001 urinary system disease Diseases 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims description 137
- 239000003814 drug Substances 0.000 claims description 127
- 229940079593 drug Drugs 0.000 claims description 101
- 210000001635 urinary tract Anatomy 0.000 claims description 44
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 208000035475 disorder Diseases 0.000 claims description 40
- 239000003826 tablet Substances 0.000 claims description 33
- 210000002307 prostate Anatomy 0.000 claims description 31
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 24
- 201000007094 prostatitis Diseases 0.000 claims description 24
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 16
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 16
- 238000013270 controlled release Methods 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 10
- 238000013268 sustained release Methods 0.000 claims description 10
- 239000012730 sustained-release form Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 206010040007 Sense of oppression Diseases 0.000 claims description 2
- 239000007894 caplet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 164
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract description 11
- 206010027566 Micturition urgency Diseases 0.000 abstract description 10
- 230000036318 urination frequency Effects 0.000 abstract description 8
- 208000008967 Enuresis Diseases 0.000 abstract description 7
- 206010036018 Pollakiuria Diseases 0.000 abstract description 7
- 229940044551 receptor antagonist Drugs 0.000 abstract description 7
- 239000002464 receptor antagonist Substances 0.000 abstract description 7
- 208000022934 urinary frequency Diseases 0.000 abstract description 7
- 208000000921 Urge Urinary Incontinence Diseases 0.000 abstract description 4
- 239000005557 antagonist Substances 0.000 abstract description 2
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 abstract 3
- 150000002148 esters Chemical class 0.000 description 218
- 150000001408 amides Chemical class 0.000 description 210
- 235000002639 sodium chloride Nutrition 0.000 description 162
- 239000002253 acid Substances 0.000 description 96
- 150000007513 acids Chemical class 0.000 description 95
- 210000003932 urinary bladder Anatomy 0.000 description 72
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 69
- -1 [ 3 H] NA Chemical compound 0.000 description 62
- 239000000203 mixture Substances 0.000 description 56
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 51
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 42
- 102000005962 receptors Human genes 0.000 description 40
- 108020003175 receptors Proteins 0.000 description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
- 238000009472 formulation Methods 0.000 description 37
- 230000005764 inhibitory process Effects 0.000 description 37
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 37
- 239000002552 dosage form Substances 0.000 description 33
- 238000012377 drug delivery Methods 0.000 description 33
- 239000013543 active substance Substances 0.000 description 30
- FVIVKIGLBDRWNR-UHFFFAOYSA-N 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine Chemical compound N1=C2SC(C)=CC2=C(C=2C(=CC=CC=2)F)N=C1N1CCNCC1 FVIVKIGLBDRWNR-UHFFFAOYSA-N 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 29
- 239000011780 sodium chloride Substances 0.000 description 29
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 24
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 24
- 229920000642 polymer Polymers 0.000 description 24
- 238000012384 transportation and delivery Methods 0.000 description 23
- 241000700159 Rattus Species 0.000 description 22
- 230000027939 micturition Effects 0.000 description 22
- 230000027455 binding Effects 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 229920001223 polyethylene glycol Polymers 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 18
- 239000002202 Polyethylene glycol Substances 0.000 description 17
- 235000011054 acetic acid Nutrition 0.000 description 17
- 238000001647 drug administration Methods 0.000 description 17
- 238000011049 filling Methods 0.000 description 17
- 238000001802 infusion Methods 0.000 description 17
- 239000003446 ligand Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 16
- 229960002748 norepinephrine Drugs 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000463 material Substances 0.000 description 15
- 229940076279 serotonin Drugs 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 239000006071 cream Substances 0.000 description 14
- 210000000278 spinal cord Anatomy 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 12
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 12
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 12
- 108010052164 Sodium Channels Proteins 0.000 description 12
- 102000018674 Sodium Channels Human genes 0.000 description 12
- 229960003638 dopamine Drugs 0.000 description 12
- 229960005343 ondansetron Drugs 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 11
- 101000935123 Homo sapiens Voltage-dependent N-type calcium channel subunit alpha-1B Proteins 0.000 description 11
- 102100025342 Voltage-dependent N-type calcium channel subunit alpha-1B Human genes 0.000 description 11
- 239000000969 carrier Substances 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 102000003922 Calcium Channels Human genes 0.000 description 10
- 108090000312 Calcium Channels Proteins 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000007913 intrathecal administration Methods 0.000 description 10
- 230000007794 irritation Effects 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 230000000966 norepinephrine reuptake Effects 0.000 description 10
- 239000000829 suppository Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 230000002267 hypothalamic effect Effects 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 241000282326 Felis catus Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 230000001022 anti-muscarinic effect Effects 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- 239000000017 hydrogel Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 8
- 239000002674 ointment Substances 0.000 description 8
- 239000003883 ointment base Substances 0.000 description 8
- 239000006072 paste Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000002287 radioligand Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 8
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 7
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 7
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 7
- 206010046543 Urinary incontinence Diseases 0.000 description 7
- 239000000048 adrenergic agonist Substances 0.000 description 7
- 230000001078 anti-cholinergic effect Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000001272 neurogenic effect Effects 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000005070 sphincter Anatomy 0.000 description 7
- 210000003568 synaptosome Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000003708 urethra Anatomy 0.000 description 7
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 6
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 6
- DUXZAXCGJSBGDW-HXUWFJFHSA-N Desfesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-HXUWFJFHSA-N 0.000 description 6
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000007327 Protamines Human genes 0.000 description 6
- 108010007568 Protamines Proteins 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000000812 cholinergic antagonist Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002567 electromyography Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 239000012669 liquid formulation Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 229950008679 protamine sulfate Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000000697 serotonin reuptake Effects 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 230000002048 spasmolytic effect Effects 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000003152 bradykinin antagonist Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- MSJQCBORNZDNDU-UHFFFAOYSA-D decasodium 3-methoxy-6-[2-(6-methoxy-4,5-disulfonatooxyoxan-3-yl)oxy-5-[5-(5-methoxy-3,4-disulfonatooxyoxan-2-yl)oxy-3,4-disulfonatooxyoxan-2-yl]oxy-4-sulfonatooxyoxan-3-yl]oxy-4,5-disulfonatooxyoxane-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].COC1COC(OC2COC(OC3COC(OC4COC(OC)C(OS([O-])(=O)=O)C4OS([O-])(=O)=O)C(OC4OC(C(OC)C(OS([O-])(=O)=O)C4OS([O-])(=O)=O)C([O-])=O)C3OS([O-])(=O)=O)C(OS([O-])(=O)=O)C2OS([O-])(=O)=O)C(OS([O-])(=O)=O)C1OS([O-])(=O)=O MSJQCBORNZDNDU-UHFFFAOYSA-D 0.000 description 5
- 230000002825 dopamine reuptake Effects 0.000 description 5
- 239000013583 drug formulation Substances 0.000 description 5
- 229940043249 elmiron Drugs 0.000 description 5
- 229960002870 gabapentin Drugs 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 239000002840 nitric oxide donor Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229960005434 oxybutynin Drugs 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000000611 regression analysis Methods 0.000 description 5
- 229960003855 solifenacin Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000004611 spectroscopical analysis Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- JZQKKSLKJUAGIC-NSHDSACASA-N (S)-(-)-pindolol Chemical compound CC(C)NC[C@H](O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-NSHDSACASA-N 0.000 description 4
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 description 4
- RVMBDLSFFNKKLG-SFHVURJKSA-N 2-[4-[2-[[(2s)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]-n-(2-methoxyethyl)acetamide Chemical compound C1=CC(OCC(=O)NCCOC)=CC=C1OCCNC[C@H](O)COC1=CC=CC=C1 RVMBDLSFFNKKLG-SFHVURJKSA-N 0.000 description 4
- 206010069918 Bacterial prostatitis Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000004821 Contact adhesive Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 102000010909 Monoamine Oxidase Human genes 0.000 description 4
- 108010062431 Monoamine oxidase Proteins 0.000 description 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 4
- 206010029279 Neurogenic bladder Diseases 0.000 description 4
- 229940122540 Neurokinin receptor antagonist Drugs 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 4
- 229960002430 atomoxetine Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000000133 brain stem Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- XOEVKNFZUQEERE-UHFFFAOYSA-N flavoxate hydrochloride Chemical compound Cl.C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 XOEVKNFZUQEERE-UHFFFAOYSA-N 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000003365 glass fiber Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000003149 muscarinic antagonist Substances 0.000 description 4
- 229940127240 opiate Drugs 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000003351 stiffener Substances 0.000 description 4
- 230000002889 sympathetic effect Effects 0.000 description 4
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 206010005052 Bladder irritation Diseases 0.000 description 3
- UMQUQWCJKFOUGV-UHFFFAOYSA-N CGP 12177 Chemical compound CC(C)(C)NCC(O)COC1=CC=CC2=C1NC(=O)N2 UMQUQWCJKFOUGV-UHFFFAOYSA-N 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 238000001135 Friedman test Methods 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 102000009493 Neurokinin receptors Human genes 0.000 description 3
- 108050000302 Neurokinin receptors Proteins 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical group [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- GQPXYJNXTAFDLT-UHFFFAOYSA-L disodium;(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate Chemical compound [Na+].[Na+].O=C1N(COP([O-])(=O)[O-])C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 GQPXYJNXTAFDLT-UHFFFAOYSA-L 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 229960002866 duloxetine Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960000855 flavoxate Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000865 liniment Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229950001588 ramosetron Drugs 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 229960004274 stearic acid Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 3
- 238000013271 transdermal drug delivery Methods 0.000 description 3
- 239000006217 urethral suppository Substances 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 3
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 2
- HQRSMNLSFMUJPL-KOSHJBKYSA-N (2r)-n-[1-[(6-aminopyridin-2-yl)methyl]piperidin-4-yl]-2-[(1r)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide Chemical compound NC1=CC=CC(CN2CCC(CC2)NC(=O)[C@@](O)([C@H]2CC(F)(F)CC2)C=2C=CC=CC=2)=N1 HQRSMNLSFMUJPL-KOSHJBKYSA-N 0.000 description 2
- TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 2
- XTBQNQMNFXNGLR-MKSBGGEFSA-N (2s)-1-(2-ethylphenoxy)-3-[[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]propan-2-ol;oxalic acid Chemical compound OC(=O)C(O)=O.CCC1=CC=CC=C1OC[C@@H](O)CN[C@@H]1C2=CC=CC=C2CCC1 XTBQNQMNFXNGLR-MKSBGGEFSA-N 0.000 description 2
- GCDHMGROXQUFNR-HEVIKAOCSA-N (2s)-n-[(2s)-1-(tert-butylamino)-1-oxo-3-(4-phenylmethoxyphenyl)propan-2-yl]-2-[(4-tert-butylphenyl)methyl-methylamino]-4-methylpentanamide Chemical compound CN([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(OCC=2C=CC=CC=2)=CC=1)C(=O)NC(C)(C)C)CC1=CC=C(C(C)(C)C)C=C1 GCDHMGROXQUFNR-HEVIKAOCSA-N 0.000 description 2
- XTMOQAKCOFLCRZ-UHFFFAOYSA-N (4-acetamidophenyl) 4-nitrooxybutanoate Chemical compound CC(=O)NC1=CC=C(OC(=O)CCCO[N+]([O-])=O)C=C1 XTMOQAKCOFLCRZ-UHFFFAOYSA-N 0.000 description 2
- LDXQLWNPGRANTO-GOSISDBHSA-N (9r)-7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C([C@H](CN(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C1=O)C)CN(C(C2=NC=CC=C22)=O)C1=C2C1=CC=C(C)C=C1 LDXQLWNPGRANTO-GOSISDBHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 2
- PWWDCRQZITYKDV-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-ylbenzimidazole Chemical compound C1CNCCN1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- GZXONPGTMHLBKQ-UTONKHPSSA-N 2,3-dihydroindol-1-yl-[(5r)-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methanone;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2N1C(=O)[C@H]1CC(NC=N2)=C2CC1 GZXONPGTMHLBKQ-UTONKHPSSA-N 0.000 description 2
- GBTKANSDFYFQBK-UHFFFAOYSA-N 2,6-dimethyl-n-(5-methyl-1,2-oxazol-3-yl)benzamide Chemical compound O1C(C)=CC(NC(=O)C=2C(=CC=CC=2C)C)=N1 GBTKANSDFYFQBK-UHFFFAOYSA-N 0.000 description 2
- DMIIPLIHVIZAQT-UHFFFAOYSA-N 2-(3,3-diphenylpropoxy)-2-(1-methylpiperidin-4-yl)acetic acid Chemical compound CN1CCC(CC1)C(C(=O)O)OCCC(C2=CC=CC=C2)C3=CC=CC=C3 DMIIPLIHVIZAQT-UHFFFAOYSA-N 0.000 description 2
- ZGGNJJJYUVRADP-ACJLOTCBSA-N 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(Cl)C=CC=1)C1=CC=C(OCC(O)=O)C=C1 ZGGNJJJYUVRADP-ACJLOTCBSA-N 0.000 description 2
- VMMYRRFPMAGXNP-BTYIYWSLSA-N 2-[4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC(C)=C(OCC(O)=O)C=C1C VMMYRRFPMAGXNP-BTYIYWSLSA-N 0.000 description 2
- MXWICZOXPUWAHY-HNNXBMFYSA-N 2-[4-[2-[[(2s)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]acetic acid Chemical compound C([C@H](O)COC=1C=CC=CC=1)NCCOC1=CC=C(OCC(O)=O)C=C1 MXWICZOXPUWAHY-HNNXBMFYSA-N 0.000 description 2
- IOJUJUOXKXMJNF-UHFFFAOYSA-N 2-acetyloxybenzoic acid [3-(nitrooxymethyl)phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1 IOJUJUOXKXMJNF-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 2
- HGMITUYOCPPQLE-UHFFFAOYSA-N 3-quinuclidinyl benzilate Chemical compound C1N(CC2)CCC2C1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 HGMITUYOCPPQLE-UHFFFAOYSA-N 0.000 description 2
- SAURKKOJWIFYSR-UHFFFAOYSA-N 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine;hydrate;hydrochloride Chemical compound O.Cl.N1=C2SC(C)=CC2=C(C=2C(=CC=CC=2)F)N=C1N1CCNCC1 SAURKKOJWIFYSR-UHFFFAOYSA-N 0.000 description 2
- MRDFTYCZRBLNLG-UHFFFAOYSA-N 4-(2-methyl-1h-imidazol-5-yl)-2,2-diphenylbutanamide Chemical compound N1C(C)=NC=C1CCC(C(N)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 MRDFTYCZRBLNLG-UHFFFAOYSA-N 0.000 description 2
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 101000594607 Conus magus Omega-conotoxin MVIIA Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101710134516 Des-Arg9-bradykinin Proteins 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- BXSVDJUWKSRQMD-ITMJLNKNSA-N O.O.CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c3ccccc3.CN4[C@@H]5CC[C@H]4C[C@H](C5)OC(=O)[C@H](CO)c6ccccc6.OS(=O)(=O)O Chemical compound O.O.CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c3ccccc3.CN4[C@@H]5CC[C@H]4C[C@H](C5)OC(=O)[C@H](CO)c6ccccc6.OS(=O)(=O)O BXSVDJUWKSRQMD-ITMJLNKNSA-N 0.000 description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 2
- 101100272974 Panax ginseng CYP716A47 gene Proteins 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- XLBIBBZXLMYSFF-UHFFFAOYSA-M Propantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 XLBIBBZXLMYSFF-UHFFFAOYSA-M 0.000 description 2
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 description 2
- KFUJMHHNLGCTIJ-UHFFFAOYSA-N Propiverine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CC[NH+](C)CC1 KFUJMHHNLGCTIJ-UHFFFAOYSA-N 0.000 description 2
- 206010050662 Prostate infection Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PDOCBJADCWMDGL-UHFFFAOYSA-N Sipatrigine Chemical compound C1CN(C)CCN1C1=NC=C(C=2C(=C(Cl)C=C(Cl)C=2)Cl)C(N)=N1 PDOCBJADCWMDGL-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- RXZMMZZRUPYENV-VROPFNGYSA-N Solifenacin succinate Chemical compound OC(=O)CCC(O)=O.C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 RXZMMZZRUPYENV-VROPFNGYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010050822 Suprapubic pain Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- XTJCLNXSOMGJKB-UHFFFAOYSA-N [1-[2-but-1-ynyl-4-(diethylamino)phenyl]cyclohexyl] 2-hydroxyacetate Chemical compound CCC#CC1=CC(N(CC)CC)=CC=C1C1(OC(=O)CO)CCCCC1 XTJCLNXSOMGJKB-UHFFFAOYSA-N 0.000 description 2
- WTAVOESJEWSDJC-OBOLPPCUSA-N [2-methoxy-4-[(E)-3-(4-nitrooxybutoxy)-3-oxoprop-1-enyl]phenyl] (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound COc1cc(\C=C\C(=O)OCCCCO[N+]([O-])=O)ccc1OC(=O)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C WTAVOESJEWSDJC-OBOLPPCUSA-N 0.000 description 2
- CTHNKWFUDCMLIQ-UHFFFAOYSA-N [4-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=C(CO[N+]([O-])=O)C=C1 CTHNKWFUDCMLIQ-UHFFFAOYSA-N 0.000 description 2
- VCEHWDBVPZFHAG-POFDKVPJSA-N [des-Arg(9)]-bradykinin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 VCEHWDBVPZFHAG-POFDKVPJSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229960003550 alosetron Drugs 0.000 description 2
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 2
- 229950005951 azasetron Drugs 0.000 description 2
- 229950007840 bemesetron Drugs 0.000 description 2
- MNJNPLVXBISNSX-WDNDVIMCSA-N bemesetron Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC(Cl)=C1 MNJNPLVXBISNSX-WDNDVIMCSA-N 0.000 description 2
- 229940090012 bentyl Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000009956 central mechanism Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- SPKBYQZELVEOLL-QDMKHBRRSA-N chembl2111147 Chemical compound N([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC2=C1OC(C)(C)C2 SPKBYQZELVEOLL-QDMKHBRRSA-N 0.000 description 2
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 2
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 2
- 229950009941 chloralose Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000037516 chromosome inversion disease Diseases 0.000 description 2
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 description 2
- 229960002099 cilansetron Drugs 0.000 description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000003350 crude synaptosomal preparation Methods 0.000 description 2
- 229960002677 darifenacin Drugs 0.000 description 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 229940076405 detrol Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940099170 ditropan Drugs 0.000 description 2
- 229960003413 dolasetron Drugs 0.000 description 2
- 230000028436 dopamine uptake Effects 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 description 2
- NQIZCDQCNYCVAS-RQBPZYBGSA-N ethyl 2-[[(7s)-7-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate;hydron;chloride Chemical compound Cl.C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)OCC)=CC=CC(Cl)=C1 NQIZCDQCNYCVAS-RQBPZYBGSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000010946 fine silver Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 2
- 229960003727 granisetron Drugs 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 description 2
- 108700023918 icatibant Proteins 0.000 description 2
- SQKXYSGRELMAAU-UHFFFAOYSA-N imidafenacin Chemical compound CC1=NC=CN1CCC(C(N)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 SQKXYSGRELMAAU-UHFFFAOYSA-N 0.000 description 2
- 229950005396 imidafenacin Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229950007467 indisetron Drugs 0.000 description 2
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 229950007654 itasetron Drugs 0.000 description 2
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229950009727 lerisetron Drugs 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- 229940080159 levsin Drugs 0.000 description 2
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960004090 maprotiline Drugs 0.000 description 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- ZFLBZHXQAMUEFS-KUHUBIRLSA-N methyl 2-[4-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=CC(Cl)=C1 ZFLBZHXQAMUEFS-KUHUBIRLSA-N 0.000 description 2
- OIZISCUUSLPUEN-LMORPYAASA-N methyl 4-[(2s)-2-[[(2s)-2-hydroxy-2-phenylethyl]amino]propyl]benzoate;(e)-4-oxopent-2-enoic acid Chemical compound CC(=O)\C=C\C(O)=O.C1=CC(C(=O)OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=CC=C1 OIZISCUUSLPUEN-LMORPYAASA-N 0.000 description 2
- 230000036453 micturition reflex Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- NZOSVDHCTCLGEB-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide;hydron;chloride Chemical compound Cl.CC1=CC=CC(C)=C1NC(=O)CC1(CCC2)N2CCC1 NZOSVDHCTCLGEB-UHFFFAOYSA-N 0.000 description 2
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 description 2
- AKFJWRDCWYYTIG-ZDUSSCGKSA-N naproxcinod Chemical compound C1=C([C@H](C)C(=O)OCCCCO[N+]([O-])=O)C=CC2=CC(OC)=CC=C21 AKFJWRDCWYYTIG-ZDUSSCGKSA-N 0.000 description 2
- 229960003759 naproxcinod Drugs 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229960001158 nortriptyline Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 208000020629 overactive bladder Diseases 0.000 description 2
- FDXQKWSTUZCCTM-UHFFFAOYSA-N oxaprotiline Chemical compound C12=CC=CC=C2C2(CC(O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-UHFFFAOYSA-N 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- 229960002131 palonosetron Drugs 0.000 description 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001734 parasympathetic effect Effects 0.000 description 2
- 230000002263 peptidergic effect Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000009955 peripheral mechanism Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 2
- 229940099209 probanthine Drugs 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical class CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 229960003510 propiverine Drugs 0.000 description 2
- 238000011471 prostatectomy Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003653 radioligand binding assay Methods 0.000 description 2
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 2
- 229960003770 reboxetine Drugs 0.000 description 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical class N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 description 2
- 229960004045 tolterodine Drugs 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229960003688 tropisetron Drugs 0.000 description 2
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 2
- 206010046494 urge incontinence Diseases 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229960001255 viloxazine Drugs 0.000 description 2
- 229940045860 white wax Drugs 0.000 description 2
- 229950004681 zacopride Drugs 0.000 description 2
- 229950001074 zatosetron Drugs 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- CFDNUNSOUUFTQO-JYMVZIKVSA-N (1r,4s,7s,10r,13s,16r)-13-benzyl-16-(1h-indol-3-ylmethyl)-7-(2-methylpropyl)-4-(2-methylsulfanylethyl)-2,5,8,11,14,17,21-heptazabicyclo[8.8.4]docosane-3,6,9,12,15,18,20-heptone Chemical compound C([C@@H]1NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H]2CC(=O)NC[C@@H](NC1=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N2)=O)CCSC)C1=CC=CC=C1 CFDNUNSOUUFTQO-JYMVZIKVSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- MHBUKMPYIGAURU-WIDHDRDXSA-N (2r)-3-[(2s)-1-[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-2-[[(2s)-2-amino-3-thiophen-2-ylpropanoyl]-[(2r)-2-[[(2s)-2-[[(2s)-2-amino-3-thiophen-2-ylpropanoyl]amino]-3-hyd Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)C(CCN=C(N)N)[C@@](C(=O)CNC(=O)[C@H]1NC[C@H](O)C1)(C(O)=O)N(C(=O)[C@@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1SC=CC=1)C(=O)[C@@H](N)CC1=CC=CS1 MHBUKMPYIGAURU-WIDHDRDXSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SHUCXUIOEAAJJL-MKSBGGEFSA-N (2s)-1-(2-ethylphenoxy)-3-[[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]propan-2-ol;hydrochloride Chemical compound Cl.CCC1=CC=CC=C1OC[C@@H](O)CN[C@@H]1C2=CC=CC=C2CCC1 SHUCXUIOEAAJJL-MKSBGGEFSA-N 0.000 description 1
- LHQWZZQCEJHGMZ-QMMMGPOBSA-N (2s)-1-propylpiperidin-1-ium-2-carboxylate Chemical compound CCCN1CCCC[C@H]1C(O)=O LHQWZZQCEJHGMZ-QMMMGPOBSA-N 0.000 description 1
- KSSWTYCYGIZZNT-UQKRIMTDSA-N (2s)-2-[(4-bromo-2,6-dimethylphenoxy)methyl]-1-methylpiperidine;hydrochloride Chemical compound Cl.CN1CCCC[C@H]1COC1=C(C)C=C(Br)C=C1C KSSWTYCYGIZZNT-UQKRIMTDSA-N 0.000 description 1
- TZWJLAAYNDPYBS-ZYEJRSMVSA-N (2s,3as,7as)-1-[(3r)-2-[(2s)-2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen- Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(O)=O)C[C@@H](O)C1 TZWJLAAYNDPYBS-ZYEJRSMVSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VSHFRHVKMYGBJL-CKUXDGONSA-N (S)-ropivacaine hydrochloride hydrate Chemical compound O.[Cl-].CCC[NH+]1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C VSHFRHVKMYGBJL-CKUXDGONSA-N 0.000 description 1
- ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- AZIZBYRGIGKTLW-UHFFFAOYSA-N 1,4-diazepin-2-one Chemical class O=C1C=NC=CC=N1 AZIZBYRGIGKTLW-UHFFFAOYSA-N 0.000 description 1
- FBOUYBDGKBSUES-KEKNWZKVSA-N 1-azabicyclo[2.2.2]octan-3-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(OC2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-KEKNWZKVSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- QMNWYGTWTXOQTP-UHFFFAOYSA-N 1h-triazin-6-one Chemical compound O=C1C=CN=NN1 QMNWYGTWTXOQTP-UHFFFAOYSA-N 0.000 description 1
- GKNHGZIVTFCIOE-GFCCVEGCSA-N 2,3-dihydroindol-1-yl-[(5r)-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methanone Chemical compound C1CC2=CC=CC=C2N1C(=O)[C@H]1CC(NC=N2)=C2CC1 GKNHGZIVTFCIOE-GFCCVEGCSA-N 0.000 description 1
- PYVTTZQYAVUMNV-UHFFFAOYSA-N 2-(benzylamino)-2-phenylacetamide Chemical class C=1C=CC=CC=1C(C(=O)N)NCC1=CC=CC=C1 PYVTTZQYAVUMNV-UHFFFAOYSA-N 0.000 description 1
- XETLOFNELZCXMX-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(4-hexoxyphenyl)-2-hydroxy-2-phenylacetate;hydrochloride Chemical compound Cl.C1=CC(OCCCCCC)=CC=C1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 XETLOFNELZCXMX-UHFFFAOYSA-N 0.000 description 1
- DBXKJORICFHAQA-UHFFFAOYSA-N 2-[(2-methylimidazol-1-yl)methyl]benzo[f]thiochromen-1-one;hydrochloride Chemical compound Cl.CC1=NC=CN1CC1=CSC2=CC=C(C=CC=C3)C3=C2C1=O DBXKJORICFHAQA-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KCAMZVQSGDBGGF-FERBBOLQSA-N 2-[4-[2-[[(2s)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]-n-(2-methoxyethyl)acetamide;hydrochloride Chemical compound Cl.C1=CC(OCC(=O)NCCOC)=CC=C1OCCNC[C@H](O)COC1=CC=CC=C1 KCAMZVQSGDBGGF-FERBBOLQSA-N 0.000 description 1
- ISFZQNYGEYAUCR-RSAXXLAASA-N 2-[4-[2-[[(2s)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]acetic acid;hydrochloride Chemical compound Cl.C([C@H](O)COC=1C=CC=CC=1)NCCOC1=CC=C(OCC(O)=O)C=C1 ISFZQNYGEYAUCR-RSAXXLAASA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AMZACPWEJDQXGW-UHFFFAOYSA-N 2-amino-n-(2,6-dimethylphenyl)propanamide;hydron;chloride Chemical compound Cl.CC(N)C(=O)NC1=C(C)C=CC=C1C AMZACPWEJDQXGW-UHFFFAOYSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- QPILHXCDZYWYLQ-UHFFFAOYSA-N 2-nonyl-1,3-dioxolane Chemical compound CCCCCCCCCC1OCCO1 QPILHXCDZYWYLQ-UHFFFAOYSA-N 0.000 description 1
- CKICBBJJCUQLPO-UHFFFAOYSA-N 2-oxaspiro[4.5]decan-3-one Chemical compound C1OC(=O)CC21CCCCC2 CKICBBJJCUQLPO-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- NNXUYJFHOVCRSM-UHFFFAOYSA-N 3-(2,3,5-trichlorophenyl)pyrazine-2,6-diamine Chemical compound NC1=NC(N)=CN=C1C1=CC(Cl)=CC(Cl)=C1Cl NNXUYJFHOVCRSM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ANAWRRAUQXSHKD-UHFFFAOYSA-N 4-[3-(tert-butylamino)-2-hydroxypropoxy]benzimidazol-2-one Chemical compound CC(C)(C)NCC(O)COC1=CC=CC2=NC(=O)N=C12 ANAWRRAUQXSHKD-UHFFFAOYSA-N 0.000 description 1
- MJCKISCWHDATBN-UHFFFAOYSA-N 4-amino-5-chloro-n-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide Chemical compound CCN1CCN=C1CNC(=O)C1=CC(Cl)=C(N)C=C1OC MJCKISCWHDATBN-UHFFFAOYSA-N 0.000 description 1
- JBSMSVZHETUQQA-UHFFFAOYSA-N 5,5-diphenylimidazolidine-2,4-dione;sodium Chemical compound [Na].N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 JBSMSVZHETUQQA-UHFFFAOYSA-N 0.000 description 1
- JEDJMKTVUPSHFW-ZRKZCGFPSA-N 5-[(2r)-2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid Chemical compound N([C@@H](CC=1C=C2OC(OC2=CC=1)(C(O)=O)C(O)=O)C)CC(O)C1=CC=CC(Cl)=C1 JEDJMKTVUPSHFW-ZRKZCGFPSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108700009060 B 4162 Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000010183 Bradykinin receptor Human genes 0.000 description 1
- 108050001736 Bradykinin receptor Proteins 0.000 description 1
- HIWKIALCXDEJPF-PKTLFSNNSA-N C(C)(=O)OOC1=CC(=CC=C1)C1CC(CCC1)NC[C@H](O)C1=CC(=CC=C1)Cl.[Na] Chemical compound C(C)(=O)OOC1=CC(=CC=C1)C1CC(CCC1)NC[C@H](O)C1=CC(=CC=C1)Cl.[Na] HIWKIALCXDEJPF-PKTLFSNNSA-N 0.000 description 1
- 0 C*N(C(C)C(*)N(C)*)c1nc(*)c(c(*)c(*)[s]2)c2n1 Chemical compound C*N(C(C)C(*)N(C)*)c1nc(*)c(c(*)c(*)[s]2)c2n1 0.000 description 1
- STKRFDKTYCNISB-UHFFFAOYSA-N C=1C=CC(Cl)=CC=1C(O)CNCCCC1=CC=C(OCC(O)=O)C=C1 Chemical compound C=1C=CC(Cl)=CC=1C(O)CNCCCC1=CC=C(OCC(O)=O)C=C1 STKRFDKTYCNISB-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010008674 Cholinergic syndrome Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- YLHAMFZCYBVACR-UHFFFAOYSA-N Cl.C1=CC=CC2=C3C(=O)C=CSC3=CC=C21 Chemical compound Cl.C1=CC=CC2=C3C(=O)C=CSC3=CC=C21 YLHAMFZCYBVACR-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000001253 Diurnal Enuresis Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 101000851593 Homo sapiens Separin Proteins 0.000 description 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 description 1
- 101000640020 Homo sapiens Sodium channel protein type 11 subunit alpha Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 125000000415 L-cysteinyl group Chemical class O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108010072184 MEN 10627 Proteins 0.000 description 1
- 108010068590 MEN 11270 Proteins 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 101100136062 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) PE10 gene Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- SNIBJKHIKIIGPR-UHFFFAOYSA-N N-desethyloxybutynin Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCNCC)C1CCCCC1 SNIBJKHIKIIGPR-UHFFFAOYSA-N 0.000 description 1
- JCOJXICRPMRJPO-UHFFFAOYSA-N N-pent-3-yn-2-yloxybenzamide Chemical compound C(C1=CC=CC=C1)(=O)NOC(C#CC)C JCOJXICRPMRJPO-UHFFFAOYSA-N 0.000 description 1
- 108700003003 NPC 567 Proteins 0.000 description 1
- RBIXVHPHNGXTCI-QJTYZATASA-N NPC-567 Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 RBIXVHPHNGXTCI-QJTYZATASA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical class N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010038967 Retrograde ejaculation Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 1
- 102100036750 Separin Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100037342 Substance-K receptor Human genes 0.000 description 1
- 102100037346 Substance-P receptor Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108010088411 Trefoil Factor-2 Proteins 0.000 description 1
- 102100039172 Trefoil factor 2 Human genes 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- JJZXGTBGAPUCHC-PBWFPOADSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-ethyl-2-oxobenzimidazole-1-carboxylate Chemical compound C1[C@@H](N2C)CC[C@@H]2CC1OC(=O)N1C2=CC=CC=C2N(CC)C1=O JJZXGTBGAPUCHC-PBWFPOADSA-N 0.000 description 1
- MNJNPLVXBISNSX-PBWFPOADSA-N [(1s,5r)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3,5-dichlorobenzoate Chemical compound C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C1=CC(Cl)=CC(Cl)=C1 MNJNPLVXBISNSX-PBWFPOADSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- IFLVGRRVGPXYON-UHFFFAOYSA-N adci Chemical compound C12=CC=CC=C2C2(C(=O)N)C3=CC=CC=C3CC1N2 IFLVGRRVGPXYON-UHFFFAOYSA-N 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 239000003994 anesthetic gas Substances 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001152 anti-nicotinic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229940118398 atridox Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- PLQZWRJQQQWOLB-UHFFFAOYSA-N benzo[d][1]benzazepine-5-carboxamide Chemical compound NC(=O)N1C=CC2=CC=CC=C2C2=CC=CC=C12 PLQZWRJQQQWOLB-UHFFFAOYSA-N 0.000 description 1
- 150000008038 benzoazepines Chemical class 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 238000013216 cat model Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- YYJGBEZPVOUBMJ-KRFCICRISA-N cyclohexyl-[(cyclohexylamino)-[[(2s)-3-naphthalen-2-yl-1-oxo-1-[4-(tributylphosphaniumylmethyl)anilino]propan-2-yl]amino]methylidene]azanium;dichloride Chemical compound Cl.[Cl-].C1=CC(C[P+](CCCC)(CCCC)CCCC)=CC=C1NC(=O)[C@@H](NC(NC1CCCCC1)=NC1CCCCC1)CC1=CC=C(C=CC=C2)C2=C1 YYJGBEZPVOUBMJ-KRFCICRISA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229940110321 dicyclomine hydrochloride Drugs 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
- SPBWMYPZWNFWES-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N SPBWMYPZWNFWES-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003233 eslicarbazepine acetate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- NQIZCDQCNYCVAS-UHFFFAOYSA-N ethyl 2-[[7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate;hydron;chloride Chemical compound Cl.C1C2=CC(OCC(=O)OCC)=CC=C2CCC1NCC(O)C1=CC=CC(Cl)=C1 NQIZCDQCNYCVAS-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002978 fesoterodine Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960003064 flavoxate hydrochloride Drugs 0.000 description 1
- RKXNZRPQSOPPRN-UHFFFAOYSA-N flecainide acetate Chemical compound CC(O)=O.FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 RKXNZRPQSOPPRN-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960001934 fosphenytoin sodium Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960003220 hydroxyzine hydrochloride Drugs 0.000 description 1
- 229960001560 hydroxyzine pamoate Drugs 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001062 icatibant Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000013284 inhibition of norepinephrine uptake Effects 0.000 description 1
- 230000008517 inhibition of serotonin uptake Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940073092 klonopin Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 229950002371 lintopride Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- LPLBKEKLEUYDEJ-UUHVOKIZSA-N men 11270 Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@H](CC=2SC=CC=2)C(=O)N[C@@H]2C(N3CC4=CC=CC=C4C[C@@H]3C(=O)N3C4CCCCC4C[C@H]3C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC2)=O)C[C@@H](O)C1 LPLBKEKLEUYDEJ-UUHVOKIZSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- RPMBYDYUVKEZJA-UHFFFAOYSA-N methoctramine Chemical compound COC1=CC=CC=C1CNCCCCCCNCCCCCCCCNCCCCCCNCC1=CC=CC=C1OC RPMBYDYUVKEZJA-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 description 1
- NFEIBWMZVIVJLQ-UHFFFAOYSA-N mexiletine hydrochloride Chemical compound [Cl-].CC([NH3+])COC1=C(C)C=CC=C1C NFEIBWMZVIVJLQ-UHFFFAOYSA-N 0.000 description 1
- 229960001070 mexiletine hydrochloride Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 208000018962 mouth sore Diseases 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- AFOFVIBWSLOHFR-GOOCMWNKSA-N n-[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-3-propan-2-ylbenzimidazole-1-carboxamide Chemical compound C1[C@@H](N2C)CC[C@@H]2CC1NC(=O)N1C2=CC=CC=C2N(C(C)C)C1=O AFOFVIBWSLOHFR-GOOCMWNKSA-N 0.000 description 1
- KOYCUQMOCJHRJC-MLOZCBHJSA-N n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;hydron;dichloride Chemical compound Cl.Cl.C1=CC=C2C(C(=O)NC3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 KOYCUQMOCJHRJC-MLOZCBHJSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 1
- 229950004211 nisoxetine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000012316 non-parametric ANOVA Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical group N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940109344 orajel Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- 229960002016 oxybutynin chloride Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010056579 pancreatic spasmolytic polypeptide Proteins 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229950010769 pilsicainide Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 150000003152 propanolamines Chemical class 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- OKGUZEVQSOSMSQ-UHFFFAOYSA-N pyrido[2,3-i][1,4]benzodiazepin-2-one Chemical class O=C1C=NC=C2C=CC3=NC=CC=C3C2=N1 OKGUZEVQSOSMSQ-UHFFFAOYSA-N 0.000 description 1
- INBRWQGQNAXUQW-UHFFFAOYSA-N pyrido[2,3-i][1,5]benzodiazepin-2-one Chemical class O=C1C=CN=C2C=CC3=NC=CC=C3C2=N1 INBRWQGQNAXUQW-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009153 reflex inhibition Effects 0.000 description 1
- 230000009158 reflex pathway Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- NXLOLUFNDSBYTP-UHFFFAOYSA-N retene Chemical compound C1=CC=C2C3=CC=C(C(C)C)C=C3C=CC2=C1C NXLOLUFNDSBYTP-UHFFFAOYSA-N 0.000 description 1
- 229960001813 ropivacaine hydrochloride Drugs 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 description 1
- 229950002652 safinamide Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229960001368 solifenacin succinate Drugs 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229950001613 soretolide Drugs 0.000 description 1
- 108010013137 spasmolytic polypeptide Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229950008418 talipexole Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- YUSMZDVTEOAHDL-NTMALXAHSA-N tert-butyl (3z)-3-(dimethylaminomethylidene)-4-oxopiperidine-1-carboxylate Chemical compound CN(C)\C=C1\CN(C(=O)OC(C)(C)C)CCC1=O YUSMZDVTEOAHDL-NTMALXAHSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- UUBIWGRMBVAUIK-UHFFFAOYSA-N tetracyclo[5.5.2.04,13.010,14]tetradeca-1(13),4,6,10(14),11-pentaene Chemical compound C1CC2=CC=C3CCC4=CC=C1C2=C43 UUBIWGRMBVAUIK-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 229960001491 trospium Drugs 0.000 description 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- 229960002811 ziconotide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46102203P | 2003-04-04 | 2003-04-04 | |
| US461022P | 2003-04-04 | ||
| US49650203P | 2003-08-20 | 2003-08-20 | |
| US496502P | 2003-08-20 | ||
| US53634104P | 2004-01-13 | 2004-01-13 | |
| US536341P | 2004-01-13 | ||
| PCT/US2004/010088 WO2004089288A2 (en) | 2003-04-04 | 2004-04-02 | Method of treating lower urinary tract disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004007225D1 DE602004007225D1 (de) | 2007-08-09 |
| DE602004007225T2 true DE602004007225T2 (de) | 2008-03-06 |
Family
ID=33162987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004007225T Expired - Fee Related DE602004007225T2 (de) | 2003-04-04 | 2004-04-02 | Methode zur behandlung von erkrankungen der unteren harnwege |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US6846823B2 (https=) |
| EP (1) | EP1539181B1 (https=) |
| JP (1) | JP2006522144A (https=) |
| AT (1) | ATE365554T1 (https=) |
| AU (1) | AU2004227945B2 (https=) |
| CA (1) | CA2519379A1 (https=) |
| DE (1) | DE602004007225T2 (https=) |
| ES (1) | ES2290741T3 (https=) |
| WO (1) | WO2004089288A2 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7085845B2 (en) * | 2001-05-09 | 2006-08-01 | Gene Fein | Method, apparatus and computer program product for identifying a playing media file and tracking associated user preferences |
| CN100355419C (zh) * | 2002-06-07 | 2007-12-19 | 安斯泰来制药有限公司 | 治疗膀胱过度活动的药物 |
| US20040180958A1 (en) * | 2002-12-13 | 2004-09-16 | Taylor Charles Price | Method of treatment |
| ES2288641T3 (es) * | 2002-12-20 | 2008-01-16 | Dynogen Pharmaceuticals Inc. | Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta. |
| DE602004003172T2 (de) * | 2003-03-21 | 2007-09-27 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals |
| EP1539181B1 (en) * | 2003-04-04 | 2007-06-27 | Dynogen Pharmaceuticals Inc. | Method of treating lower urinary tract disorders |
| WO2005011683A1 (ja) * | 2003-08-04 | 2005-02-10 | Kyorin Pharmaceutical Co., Ltd. | 経皮吸収型製剤 |
| CA2560279A1 (en) * | 2004-03-19 | 2005-09-29 | Solvay Pharmaceuticals Gmbh | Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain |
| US7820690B2 (en) | 2004-03-19 | 2010-10-26 | Solvay Pharmaceuticals Gmbh | Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist |
| WO2006042679A1 (de) * | 2004-10-18 | 2006-04-27 | Boehringer Ingelheim International Gmbh | Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts |
| WO2006066110A2 (en) * | 2004-12-14 | 2006-06-22 | The Johns Hopkins University | Cav2 RELATED COMPOSITIONS AND METHODS |
| KR20070087678A (ko) | 2004-12-20 | 2007-08-28 | 컬리지움 파마슈티칼, 인코포레이티드 | 수면 장애용 약제 조성물 |
| DK2839830T3 (da) * | 2005-01-14 | 2019-08-19 | Urigen Inc | Kits og sammensætninger til behandling af lidelser i de nedre urinveje |
| EP1855680A2 (en) * | 2005-02-25 | 2007-11-21 | Solvay Pharmaceuticals, Inc. | Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy |
| US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US20070093520A1 (en) * | 2005-04-15 | 2007-04-26 | Caras Steven D | Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject |
| US20070010543A1 (en) * | 2005-07-01 | 2007-01-11 | Dynogen Pharmaceuticals, Inc. | Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| FR2895259B1 (fr) * | 2005-12-22 | 2008-02-22 | Urosphere Sas | Methodes de traitement des incontinences urinaires |
| US20070172507A1 (en) * | 2006-01-26 | 2007-07-26 | Paul Zupkas | Transluminal drug delivery methods and devices |
| US20070172508A1 (en) * | 2006-01-26 | 2007-07-26 | Paul Zupkas | Transluminal drug delivery methods and devices |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP1991212A1 (en) * | 2006-03-08 | 2008-11-19 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| EP2068872A1 (en) * | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| EP1997807A1 (en) * | 2007-05-28 | 2008-12-03 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments |
| US20090112197A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc | Devices configured to facilitate release of nitric oxide |
| CA2673545A1 (en) * | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids |
| US20080171750A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation Of Neurogenesis With Use of Modafinil |
| US20090274722A1 (en) * | 2007-01-29 | 2009-11-05 | Ligums John E | Therapeutic Composition for the Treatment of BPH and ED |
| MX2009010000A (es) * | 2007-03-19 | 2010-03-17 | Insuline Medical Ltd | Dispositivo para el suministro de farmaco. |
| EP2136863A2 (en) * | 2007-03-19 | 2009-12-30 | Insuline Medical Ltd. | Device for drug delivery and associated connections thereto |
| US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
| US9220837B2 (en) * | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
| US8415390B2 (en) | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| AU2008259864C1 (en) * | 2007-05-30 | 2014-03-06 | Microdose Therapeutx, Inc. | Methods and compositions for administration of Oxybutynin |
| WO2008157205A2 (en) * | 2007-06-15 | 2008-12-24 | Duke University | Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp |
| US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| US20110182970A1 (en) * | 2007-10-30 | 2011-07-28 | Hyde Roderick A | Nitric oxide sensors and systems |
| US10080823B2 (en) * | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
| DK2216021T3 (da) | 2007-11-02 | 2012-11-05 | Astellas Pharma Inc | Farmaceutisk sammensætning til behandling af overaktiv blære |
| US8409133B2 (en) | 2007-12-18 | 2013-04-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
| WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| CA2743027C (en) | 2008-11-07 | 2016-04-12 | Insuline Medical Ltd. | Device and method for drug delivery |
| WO2010077669A2 (en) * | 2008-12-08 | 2010-07-08 | Teva Pharmaceutical Industries Ltd. | Palonosetron formulation |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9180263B2 (en) * | 2009-07-01 | 2015-11-10 | Microdose Therapeutx, Inc. | Laboratory animal pulmonary dosing device |
| US20110000481A1 (en) * | 2009-07-01 | 2011-01-06 | Anand Gumaste | Nebulizer for infants and respiratory compromised patients |
| ES2702753T3 (es) * | 2010-01-05 | 2019-03-05 | Microdose Therapeutx Inc | Dispositivo de inhalación |
| WO2018071435A1 (en) | 2016-10-11 | 2018-04-19 | Microdose Therapeutx, Inc. | Inhaler and methods of use thereof |
| WO2020030777A1 (en) * | 2018-08-10 | 2020-02-13 | Grünenthal GmbH | Composition for treating urinary frequency and/or urinary urgency |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3046489A (en) | 1958-11-28 | 1962-07-24 | Elcor Inc | Wide band direct coupled amplifier |
| US3161155A (en) | 1961-02-04 | 1964-12-15 | Orlandi Giorgio | Food-dough cords spacing device |
| JPS60146891A (ja) * | 1984-01-05 | 1985-08-02 | Mitsubishi Chem Ind Ltd | 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩 |
| DE3422155A1 (de) | 1984-06-14 | 1985-12-19 | Alfred Teves Gmbh, 6000 Frankfurt | Hydraulische servofahrzeugbremse |
| IE880255L (en) | 1987-01-30 | 1988-07-30 | American Home Prod | Des-epidermal growth factor activators. |
| DE3885357T2 (de) | 1987-06-29 | 1994-03-24 | Duphar Int Res | Anellierte Indolderivate. |
| US5225407A (en) | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| CA2044854A1 (en) * | 1990-07-19 | 1992-01-20 | Hong-I Chen | Method for preventing or treating urinary incontinence |
| PH30083A (en) * | 1991-02-25 | 1996-12-27 | Lilly Co Eli | Treatment of lower urinary tract disorders |
| WO1993000074A1 (en) | 1991-06-26 | 1993-01-07 | Sepracor, Inc. | Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron |
| US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| JP2699794B2 (ja) | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| JPH0616557A (ja) * | 1992-12-21 | 1994-01-25 | Mitsubishi Kasei Corp | 脳機能障害改善剤 |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| DK0855397T3 (da) | 1995-07-28 | 2001-06-25 | Dainippon Pharmaceutical Co | (R)-5-brom-N-(ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, fremgangsmåde til dets fremstilling og medicinsk præparat indeholdende denne forbindelse |
| AU702594B2 (en) | 1995-10-13 | 1999-02-25 | Duphar International Research B.V. | Process for the preparation of enantiomerically pure imidazolyl compounds |
| CA2286076C (en) | 1997-04-18 | 2006-12-12 | Janssen Pharmaceutica N.V. | Use of 5ht3 antagonists for promoting intestinal lavage |
| JPH10298078A (ja) | 1997-05-06 | 1998-11-10 | Mitsubishi Chem Corp | 抗不安薬 |
| DE19813661A1 (de) | 1997-08-01 | 1999-02-04 | Solvay Pharm Gmbh | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron |
| DE19734444A1 (de) | 1997-08-08 | 1999-02-11 | Basf Ag | 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung |
| FR2781671A1 (fr) | 1998-07-28 | 2000-02-04 | Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique |
| WO2000024716A1 (en) | 1998-10-23 | 2000-05-04 | Ajinomoto Co., Inc. | Dihydropyridine derivatives and drug compositions containing the same |
| US6272553B2 (en) * | 1998-11-20 | 2001-08-07 | Sprint Communications Company, L.P. | Multi-services communications device |
| ES2327600T3 (es) | 1999-02-18 | 2009-11-02 | Novasearch Ag | Uso de antagonistas del receptor de la 5-ht3 para el tratamiento de enfermedades musculoesqueleticas. |
| US6342496B1 (en) * | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| DE19911371A1 (de) | 1999-03-15 | 2000-09-21 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen |
| US6589570B1 (en) * | 1999-04-12 | 2003-07-08 | University Of Madras | Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation |
| DE19929197A1 (de) | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung |
| US6465458B1 (en) | 1999-07-01 | 2002-10-15 | Pharmacia & Upjohn Company | Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor |
| GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| US6846496B1 (en) * | 1999-10-15 | 2005-01-25 | Orion Corporation | Treatment of osteoporosis |
| WO2001051496A1 (en) * | 2000-01-14 | 2001-07-19 | Rhodia, Inc. | Crosslinking agents for textile finishing baths |
| PT1257277E (pt) | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
| JP2002026134A (ja) * | 2000-07-12 | 2002-01-25 | Seiko Epson Corp | 半導体集積回路の製造方法及びこの方法により製造した半導体集積回路 |
| GB0112494D0 (en) | 2001-05-22 | 2001-07-11 | Arachnova Therapeutics Ltd | New therapeutic use |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| WO2003061657A1 (en) | 2002-01-18 | 2003-07-31 | Aryx Therapeutics | 5-ht3 receptor antagonists and methods of use |
| GB0202265D0 (en) | 2002-01-31 | 2002-03-20 | Arachnova Therapeutics Ltd | New therapeutic use |
| JP2005526079A (ja) | 2002-03-15 | 2005-09-02 | サイプレス バイオサイエンス， インコーポレイテッド | 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤 |
| CA2491836C (en) | 2002-07-10 | 2011-01-25 | Arachnova Therapeutics Ltd. | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder |
| AU2003259373B2 (en) | 2002-08-29 | 2006-03-09 | Dynogen Pharmaceuticals, Inc. | New therapeutic uses of (4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-D]pyrimidine |
| MXPA05007381A (es) * | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para el tratamiento de transtornos funcionales del intestino. |
| NZ541009A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating nausea, vomiting, retching or any combination thereof |
| EP1539181B1 (en) * | 2003-04-04 | 2007-06-27 | Dynogen Pharmaceuticals Inc. | Method of treating lower urinary tract disorders |
| US7356884B2 (en) * | 2003-12-18 | 2008-04-15 | 3M Innovative Properties Company | Fastener for a display page |
-
2004
- 2004-04-02 EP EP04758741A patent/EP1539181B1/en not_active Expired - Lifetime
- 2004-04-02 AT AT04758741T patent/ATE365554T1/de not_active IP Right Cessation
- 2004-04-02 JP JP2006509595A patent/JP2006522144A/ja active Pending
- 2004-04-02 DE DE602004007225T patent/DE602004007225T2/de not_active Expired - Fee Related
- 2004-04-02 ES ES04758741T patent/ES2290741T3/es not_active Expired - Lifetime
- 2004-04-02 US US10/817,332 patent/US6846823B2/en not_active Expired - Fee Related
- 2004-04-02 CA CA002519379A patent/CA2519379A1/en not_active Abandoned
- 2004-04-02 WO PCT/US2004/010088 patent/WO2004089288A2/en not_active Ceased
- 2004-04-02 AU AU2004227945A patent/AU2004227945B2/en not_active Ceased
- 2004-06-07 US US10/863,771 patent/US20050020577A1/en not_active Abandoned
- 2004-06-07 US US10/863,770 patent/US7115606B2/en not_active Expired - Fee Related
-
2005
- 2005-05-04 US US11/122,940 patent/US20050272719A1/en not_active Abandoned
- 2005-05-06 US US11/124,580 patent/US20050282799A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004227945B2 (en) | 2006-10-26 |
| CA2519379A1 (en) | 2004-10-21 |
| DE602004007225D1 (de) | 2007-08-09 |
| US20050282799A1 (en) | 2005-12-22 |
| WO2004089288A3 (en) | 2005-04-21 |
| AU2004227945A1 (en) | 2004-10-21 |
| EP1539181B1 (en) | 2007-06-27 |
| US20050026909A1 (en) | 2005-02-03 |
| US20040209869A1 (en) | 2004-10-21 |
| EP1539181A2 (en) | 2005-06-15 |
| ES2290741T3 (es) | 2008-02-16 |
| ATE365554T1 (de) | 2007-07-15 |
| US20050272719A1 (en) | 2005-12-08 |
| EP1539181A4 (en) | 2005-12-28 |
| WO2004089288A2 (en) | 2004-10-21 |
| US20050020577A1 (en) | 2005-01-27 |
| US7115606B2 (en) | 2006-10-03 |
| US6846823B2 (en) | 2005-01-25 |
| JP2006522144A (ja) | 2006-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004007225T2 (de) | Methode zur behandlung von erkrankungen der unteren harnwege | |
| DE602004003172T2 (de) | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals | |
| US7084116B2 (en) | Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators | |
| DK2512240T3 (en) | Methods and compositions for the treatment and improvement of trigeminal autonomic cephalgias, migraines and vascular conditions | |
| US20080021074A1 (en) | Pharmaceutical Compositions and Related Methods of Treatment | |
| JP2006515327A (ja) | ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法 | |
| US20060293309A1 (en) | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors | |
| US20080175903A1 (en) | Treatment of anxiety with eszopiclone | |
| DE60315258T2 (de) | Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals | |
| CA2674303C (en) | Therapeutical uses of eslicarbazepine | |
| US7223754B2 (en) | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | |
| Dietrich et al. | Effects of topical 2% dorzolamide hydrochloride alone and in combination with 0.5% timolol maleate on intraocular pressure in normal feline eyes | |
| US8901177B2 (en) | Method of treating bladder disorders | |
| RU2224519C2 (ru) | Антиоксидантное и стимулирующее рост нервных клеток средство | |
| EP1795196A2 (en) | Method of treating lower urinary tract disorders | |
| AU2007200317A1 (en) | Method of treating lower urinary tract disorders | |
| Nishino | Anticataplectic medications | |
| Richards | Applied pharmacology pertaining to the trauma patient | |
| HK1169919A (en) | Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions | |
| HK1169919B (en) | Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions | |
| NZ543762A (en) | Use of an alpha2delta subunit calcium channel modulator such as gabapentin or pregabalin in a medicament for treating non-painful disorders of the bladder | |
| TW201103546A (en) | New use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |